ADDING MULTIMEDIA Organon Launches as New Global Women’s Health Company
Only company of its size focused on women’s health
Launching with a commitment to listen to women to understand her health needs and help identify solutions that are urgently needed
JERSEY CITY, N.J. (BUSINESS WIRE) #Health Organon (NYSE: OGN), today celebrates its launch as a global women’s health company with employees and women from around the world, as the Organon executive leadership team rings the opening bell at the New York Stock Exchange (NYSE). Recognizing the need to listen to and act on women’s experiences to address the challenges in women’s health, Organon gathered voices from around the world to create the “Wall of Voices,” a multimedia installation outside of the NYSE.
Press release content from Business Wire. The AP news staff was not involved in its creation.
Merck Hosts Organon Investor Day Outlining New Company’s Vision, Focus and Business Model for Sustained Growth
May 3, 2021 GMT
KENILWORTH, N.J. (BUSINESS WIRE) May 3, 2021
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today will host Organon management at a meeting with the investment community. Management will detail plans for how Organon is expected to drive sustainable growth and shareholder value as a standalone company.
“The spinoff of Organon will help Merck become a leaner, more focused and agile company with stronger growth, and will enable significant operating efficiencies. Organon, as a standalone company, will be better positioned to realize its potential and to have a meaningful impact, particularly in women’s health”, said Rob Davis, president, Merck. “We believe this transaction will create value for the patients both companies serve and
decisivemarketsinsightsMay 3, 2021
The
Postpartum Haemorrhage Treatment Device Market is expected to grow at a CAGR of 6.1% and is poised to reach US$XX Billion by 2027 as compared to US$XX Billion in 2020. The factors leading to this extraordinary growth is attributed to various market dynamics discussed in the report. Our experts have examined the market from a 360 degree perspective thereby producing a report which is definitely going to impact your business decisions.
In order to make a pre-order inquiry, kindly click on the link below:-
The Market research analysis report by Decisive Markets Insights is a detailed study and guide of market share, market size, and market dynamics and thus, it is an illustrative sample demonstration of the current and the future market trends in the industry.
Merck Announces First-Quarter 2021 Financial Results
First-Quarter 2021 Sales Were $12.1 Billion, In-Line with First-Quarter 2020; Excluding the Impact from Foreign Exchange, Sales Declined 1% First-Quarter 2021 Sales Reflect Strong Underlying Performance of KEYTRUDA, Lynparza, BRIDION and Animal Health, Which Was Offset by COVID-19 Pandemic Impacts to Patient Access, Particularly for Vaccines First-Quarter 2021 GAAP EPS Was $1.25; First-Quarter Non-GAAP EPS Was $1.40 … First-Quarter 2021 Sales Were $12.1 Billion, In-Line with First-Quarter 2020; Excluding the Impact from Foreign Exchange, Sales Declined 1% First-Quarter 2021 Sales Reflect Strong Underlying Performance of KEYTRUDA, Lynparza, BRIDION and Animal Health, Which Was Offset by COVID-19 Pandemic Impacts to Patient Access, Particularly for Vaccines First-Quarter 2021 GAAP EPS Was $1.25; First-Quarter Non-GAAP EPS Was $1.40